Australia's Sigma Eyes Bid for Symbion (Australia)
This article was originally published in PharmAsia News
Sigma Pharmaceuticals of Australia plans to join the fray and make a bid to purchase Symbion Health's large network of pharmacy services and consumer pharmaceutical businesses in Australia. Healthscope and its partners already have bid 2.86 billion Australian dollars for it. Sigma's interest may derail that deal. (Click here for more
You may also be interested in...
FDA's COVID-19 Naughty List Now Includes Marketers Of Copper Germ Stoppers, ‘24-Hour’ Hand Sanitizer
Warning letters issued by the US FDA on 28 May target two companies using COVID-19 and other disease-prevention claims to market purported germ-killing products, including a rub touted as 24-hour protection and a line of copper rollers and other implements to disinfect hands and personal items.
Industry-funded survey by Charles River Associates explores diverse perceptions about pricing for high-cost cell treatments – including curative cell and gene therapy – among various stakeholder groups.
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.